STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody
Authors
Keywords
-
Journal
Nature Communications
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-10-14
DOI
10.1038/ncomms9499
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC
- (2017) D. D. Karp et al. JOURNAL OF CLINICAL ONCOLOGY
- IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
- (2015) Eugenia R. Zanella et al. Science Translational Medicine
- Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells
- (2015) Pamela J. Maxwell et al. Oncotarget
- Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Corey J. Langer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
- (2013) Cynthia X. Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-κB pathways induced by paracrine cytokines
- (2013) Yao-Hui Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway
- (2013) Dong Hoon Shin et al. JNCI-Journal of the National Cancer Institute
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
- (2013) Alicia S Chung et al. NATURE MEDICINE
- Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)
- (2012) S. Schmitz et al. ANNALS OF ONCOLOGY
- Targeting the Insulin-like Growth Factor Axis for the Development of Novel Therapeutics in Oncology
- (2012) J. Gao et al. CANCER RESEARCH
- Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?
- (2012) Andrea Gombos et al. INVESTIGATIONAL NEW DRUGS
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
- (2012) Yu Sun et al. NATURE MEDICINE
- Mesenchymal stem cells promote growth and angiogenesis of tumors in mice
- (2012) W-H Huang et al. ONCOGENE
- Met Receptor Tyrosine Kinase Signaling Induces Secretion of the Angiogenic Chemokine Interleukin-8/CXCL8 in Pancreatic Cancer
- (2012) Kristen S. Hill et al. PLoS One
- Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
- (2011) Paolo Cirri et al. CANCER AND METASTASIS REVIEWS
- Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
- (2011) T. Shree et al. GENES & DEVELOPMENT
- Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer
- (2011) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
- (2011) Heribert Juergens et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group
- (2011) Suman Malempati et al. JOURNAL OF CLINICAL ONCOLOGY
- Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma
- (2011) J. Abraham et al. MOLECULAR CANCER THERAPEUTICS
- Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2
- (2011) H. K. Bid et al. MOLECULAR CANCER THERAPEUTICS
- Phospholipase C and Protein Kinase C-β 2 Mediate Insulin-Like Growth Factor II-Dependent Sphingosine Kinase 1 Activation
- (2011) Hesham M. El-Shewy et al. MOLECULAR ENDOCRINOLOGY
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
- (2011) Bin-Zhi Qian et al. NATURE
- Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression
- (2011) Mina J Bissell et al. NATURE MEDICINE
- Tumor angiogenesis: molecular pathways and therapeutic targets
- (2011) Sara M Weis et al. NATURE MEDICINE
- Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling
- (2011) C Garofalo et al. ONCOGENE
- Introduction of SV40ER and hTERT into mammospheres generates breast cancer cells with stem cell properties
- (2011) A N Paranjape et al. ONCOGENE
- Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model
- (2010) F. Huang et al. CANCER RESEARCH
- Identification of a Metalloprotease-Chemokine Signaling System in the Ovarian Cancer Microenvironment: Implications for Antiangiogenic Therapy
- (2010) A. Agarwal et al. CANCER RESEARCH
- The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer
- (2010) Roy M. Bremnes et al. Journal of Thoracic Oncology
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
- (2010) D. B. Ulanet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemokines and chemokine receptors: new insights into cancer-related inflammation
- (2010) Gwendal Lazennec et al. TRENDS IN MOLECULAR MEDICINE
- Cixutumumab
- (2009) Kevin P McKian et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLC 2 axis
- (2008) Y.-S. Maeng et al. BLOOD
- Interactions between microenvironment and cancer cells in two animal models of bone metastasis
- (2008) S Blouin et al. BRITISH JOURNAL OF CANCER
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- The Interleukin-8 Pathway in Cancer
- (2008) D. J.J. Waugh et al. CLINICAL CANCER RESEARCH
- CXCL8/IL-8 and CXCL12/SDF-1α co-operatively promote invasiveness and angiogenesis in pancreatic cancer
- (2008) Yoichi Matsuo et al. INTERNATIONAL JOURNAL OF CANCER
- Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3null mice intrahepatic engrafted with cord blood-derived CD34+ cells
- (2008) Seiji Okada et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started